512,367 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by CenterBook Partners LP

CenterBook Partners LP purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 512,367 shares of the company’s stock, valued at approximately $5,149,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of ARS Pharmaceuticals by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock worth $35,178,000 after buying an additional 237,630 shares during the period. Aberdeen Group plc grew its stake in ARS Pharmaceuticals by 106.1% in the 3rd quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock valued at $31,125,000 after acquiring an additional 1,594,447 shares during the period. Profund Advisors LLC increased its holdings in ARS Pharmaceuticals by 54.1% in the 3rd quarter. Profund Advisors LLC now owns 26,330 shares of the company’s stock worth $265,000 after acquiring an additional 9,242 shares in the last quarter. American Assets Inc. purchased a new stake in ARS Pharmaceuticals in the 3rd quarter worth $553,000. Finally, Principal Financial Group Inc. raised its position in ARS Pharmaceuticals by 38.7% during the third quarter. Principal Financial Group Inc. now owns 76,884 shares of the company’s stock worth $773,000 after acquiring an additional 21,438 shares during the period. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Stock Performance

NASDAQ:SPRY opened at $9.45 on Thursday. The company has a market cap of $934.13 million, a P/E ratio of -11.67 and a beta of 0.79. ARS Pharmaceuticals, Inc. has a twelve month low of $6.66 and a twelve month high of $18.90. The company’s 50-day moving average price is $10.59 and its 200-day moving average price is $10.72. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14.

Analysts Set New Price Targets

SPRY has been the topic of several research analyst reports. Zacks Research lowered shares of ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Roth Mkm initiated coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective for the company. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.67.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.